These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Decreased expressions of CD1d molecule on liver dendritic cells in subcutaneous tumor bearing mice. Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Yamamoto M; Fujita Y; Miyagi T; Ohkawa K; Hayashi N J Hepatol; 2008 Nov; 49(5):779-86. PubMed ID: 18760855 [TBL] [Abstract][Full Text] [Related]
4. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Ishikawa A; Motohashi S; Ishikawa E; Fuchida H; Higashino K; Otsuji M; Iizasa T; Nakayama T; Taniguchi M; Fujisawa T Clin Cancer Res; 2005 Mar; 11(5):1910-7. PubMed ID: 15756017 [TBL] [Abstract][Full Text] [Related]
5. Enhanced tumor metastasis in response to blockade of the chemokine receptor CXCR6 is overcome by NKT cell activation. Cullen R; Germanov E; Shimaoka T; Johnston B J Immunol; 2009 Nov; 183(9):5807-15. PubMed ID: 19812206 [TBL] [Abstract][Full Text] [Related]
6. Regulation by Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 of alpha-galactosylceramide-induced antimetastatic activity and Th1 and Th2 responses of NKT cells. Okajo J; Kaneko Y; Murata Y; Tomizawa T; Okuzawa C; Saito Y; Kaneko Y; Ishikawa-Sekigami T; Okazawa H; Ohnishi H; Matozaki T; Nojima Y J Immunol; 2007 May; 178(10):6164-72. PubMed ID: 17475843 [TBL] [Abstract][Full Text] [Related]
7. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide. Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891 [TBL] [Abstract][Full Text] [Related]
8. Cutting edge: activation of NK T cells by CD1d and alpha-galactosylceramide directs conventional T cells to the acquisition of a Th2 phenotype. Singh N; Hong S; Scherer DC; Serizawa I; Burdin N; Kronenberg M; Koezuka Y; Van Kaer L J Immunol; 1999 Sep; 163(5):2373-7. PubMed ID: 10452969 [TBL] [Abstract][Full Text] [Related]
9. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. Carnaud C; Lee D; Donnars O; Park SH; Beavis A; Koezuka Y; Bendelac A J Immunol; 1999 Nov; 163(9):4647-50. PubMed ID: 10528160 [TBL] [Abstract][Full Text] [Related]
10. In vitro anti-tumour activity of alpha-galactosylceramide-stimulated human invariant Valpha24+NKT cells against melanoma. Kikuchi A; Nieda M; Schmidt C; Koezuka Y; Ishihara S; Ishikawa Y; Tadokoro K; Durrant S; Boyd A; Juji T; Nicol A Br J Cancer; 2001 Sep; 85(5):741-6. PubMed ID: 11531261 [TBL] [Abstract][Full Text] [Related]
11. Phenotypical and functional alterations during the expansion phase of invariant Valpha14 natural killer T (Valpha14i NKT) cells in mice primed with alpha-galactosylceramide. Ikarashi Y; Iizuka A; Koshidaka Y; Heike Y; Takaue Y; Yoshida M; Kronenberg M; Wakasugi H Immunology; 2005 Sep; 116(1):30-7. PubMed ID: 16108815 [TBL] [Abstract][Full Text] [Related]
12. Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo. Nagaraj S; Ziske C; Strehl J; Messmer D; Sauerbruch T; Schmidt-Wolf IG Int Immunol; 2006 Aug; 18(8):1279-83. PubMed ID: 16772371 [TBL] [Abstract][Full Text] [Related]
13. Comparison of clinical and immunological effects of intravenous and intradermal administration of α-galactosylceramide (KRN7000)-pulsed dendritic cells. Nicol AJ; Tazbirkova A; Nieda M Clin Cancer Res; 2011 Aug; 17(15):5140-51. PubMed ID: 21653690 [TBL] [Abstract][Full Text] [Related]
14. [Ex vivo expansion of Valpha24 natural killer T cells with alpha-galactosylceramide]. Huang Y; Jiang EL; Zhou Z; He Y; Wang M; Liu QG; Zhai WJ; Han MZ Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2005 Jun; 27(3):315-20. PubMed ID: 16038267 [TBL] [Abstract][Full Text] [Related]
16. Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer. Ko SY; Lee KA; Youn HJ; Kim YJ; Ko HJ; Heo TH; Kweon MN; Kang CY Eur J Immunol; 2007 Aug; 37(8):2127-37. PubMed ID: 17615581 [TBL] [Abstract][Full Text] [Related]
17. Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance. Ito H; Ando K; Ishikawa T; Nakayama T; Taniguchi M; Saito K; Imawari M; Moriwaki H; Yokochi T; Kakumu S; Seishima M Int Immunol; 2008 Jul; 20(7):869-79. PubMed ID: 18487227 [TBL] [Abstract][Full Text] [Related]
18. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo. Chamoto K; Takeshima T; Kosaka A; Tsuji T; Matsuzaki J; Togashi Y; Ikeda H; Nishimura T Immunol Lett; 2004 Aug; 95(1):5-11. PubMed ID: 15325792 [TBL] [Abstract][Full Text] [Related]
19. Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. van der Vliet HJ; Molling JW; Nishi N; Masterson AJ; Kölgen W; Porcelli SA; van den Eertwegh AJ; von Blomberg BM; Pinedo HM; Giaccone G; Scheper RJ Cancer Res; 2003 Jul; 63(14):4101-6. PubMed ID: 12874013 [TBL] [Abstract][Full Text] [Related]
20. Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Kawano T; Nakayama T; Kamada N; Kaneko Y; Harada M; Ogura N; Akutsu Y; Motohashi S; Iizasa T; Endo H; Fujisawa T; Shinkai H; Taniguchi M Cancer Res; 1999 Oct; 59(20):5102-5. PubMed ID: 10537282 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]